Johnson Johnson Healthcare

历史时间线

• 1886 — Three brothers (Robert, James, and Edward Johnson) founded J&J in New Brunswick, New Jersey, pioneering the mass production of sterile surgical dressings
• 1920 — Earle Dickson, a J&J employee, invented the Band-Aid for his wife who frequently cut herself cooking — it became one of the best-selling products in history
• 1944 — J&J went public and began its decades-long streak of consecutive dividend increases (now spanning 60+ years)
• 2023 — J&J completed the spinoff of its consumer health division (Kenvue) to focus exclusively on pharmaceuticals and medical devices

商业模式

Following the 2023 Kenvue spinoff, Johnson & Johnson operates through two segments: Innovative Medicine (pharmaceuticals — oncology, immunology, neuroscience, pulmonary hypertension) and MedTech (medical devices and diagnostics — surgery, orthopedics, vision, cardiovascular). The pharmaceutical business generates higher margins (~70% gross margin) and drives growth, while MedTech provides steady cash flow from recurring procedural demand. The company's diversification across drug development and medical equipment reduces exposure to any single patent cliff or product recall.

护城河分析

J&J's moat derives from its scale in both R&D and commercialization across therapeutic areas, with a deep pipeline of drug candidates and a MedTech portfolio spanning thousands of products used in nearly every hospital worldwide. The company's 140-year brand reputation, combined with regulatory expertise accumulated across hundreds of FDA submissions, creates barriers to entry that new competitors cannot quickly overcome — though recent litigation exposure (talc lawsuits) has tested the resilience of this moat.

关键数据

有趣事实

The Band-Aid was invented by an employee, Earle Dickson, in his kitchen as a personal solution for his wife Josephine, who frequently burned and cut herself while cooking. He brought the prototype to his supervisors at J&J, who recognized its potential and made it a standard product — eventually selling billions of units. The talc powder controversy, which resulted in billions of dollars in jury verdicts alleging asbestos contamination in baby powder, led J&J to discontinue talc-based products in North America in 2020 and globally in 2023, marking one of the most significant legal challenges in corporate history.